Recon: Pfizer plans to submit Lyme vaccine despite primary endpoint miss; FDA approves BMS’ Hodgkin’s lymphoma drug

• Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle (STAT)
• US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma (Reuters)
• Rhythm's therapy becomes first FDA-approved treatment for brain damage-related obesity (Reuters)
• FDA posts photos of Indian drugmaking facility cited in warning letter (Endpoints)
• FDA flags seizure risk with certain Parkinson's drugs (Reuters)
• FTC creates healthcare task force (MedTech Dive)

• Iran war has not disrupted pharma supply chains. That could change if conflict is prolonged (STAT)
• Britain medicine supply at risk if Middle East conflict persists, trade group warns (Reuters)
• Novartis to buy experimental breast cancer drug in up to $3 billion deal (Reuters)
• WuXi AppTec’s bet on the US pays off as revenues dip elsewhere (Endpoints)
• Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy (Reuters)
• Kent meningitis outbreak triggers surge in UK vaccine demand, policy debate (Reuters)
• Beijing-backed brain chip firm says it is 3 years behind Musk's Neuralink (Reuters)

• Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports (Reuters)
• Insmed drug benefits patients with rare, bacterial lung disease, study shows (STAT)
• Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections (STAT)
• FDA solicits feedback on controversial national priority voucher review pathway (Fierce Pharma)
• Doctronic raises $40 million as race to apply AI in clinical care heats up (STAT)
• Aurinia's CEO and C-suite are out as investor Kevin Tang consolidates control (Endpoints)
• Former Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech Oryon (Endpoints)
• A California startup wins $180M in support as Sanofi rebuilds presence in T cell engagers (Endpoints)
• Oryon Cell Therapies launches with $21 million to advance Parkinson's treatment (Reuters)

• Labcorp closes purchase of New York pathology reference lab assets (MedTech Dive)
• Abbott to close $21B Exact Sciences acquisition Monday (MedTech Dive)
• CISA urges organizations to harden endpoint security following Stryker attack (MedTech Dive)
• In Medtech, AI Is No Longer An Add-On, It’s Becoming Part of Operations, LSI Panelists Said (MedTech Insight)
• Screenless, Smartphone-Controlled Pump: MiniMed Flex Cleared By FDA Weeks After IPO (MedTech Insight)
• Verily Raises $300M To Advance Precision Health Platform As Independent Firm (MedTech Insight)
• MEPs Vote To Delay And Simplify AI Act Rules For Medical Devices (MedTech Insight)

• After funding collapse, what’s next for food startups? (Food Dive)
• Bill to lift ban on transporting raw milk is back (Food Safety News)

• Her son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey (STAT)
• Epic says it has uncovered rot in patient record sharing. Will HHS act? (STAT)
• The AI push in health care is deepening medicine’s trust crisis (STAT)
• EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug (Reuters)